At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
SYR-472drug
Likely dose
SYR-472 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-label, Crossover Phase 1 Study to Evaluate the Bioequivalence Following a Single Oral Dose Administration of SYR-472 25mg and 50mg Tablets in Healthy Adult Male Subjects
In Brief
A Phase 1 clinical trial evaluating SYR-472 for Healthy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the bioequivalence of 2 tablets of SYR-472 25 milligram (mg) and 1 tablet of SYR-472 50 mg administered to healthy adult males.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMar 2015
Primary CompletionApr 2015
TodayJul 2026
First PostedFeb 26, 2015
Enrollment StartMar 1, 2015
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.3 years ago
Interventions
SYR-472drug
SYR-472 25mg, 50mg